Global Radiopharmaceuticals Market Size, Share, and Growth & Trends Analysis By End User (Hospitals and Clinics, Medical Imaging Centers, Others) By Radioisotope (Technetium 99m, Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, Others) By Application (Cancer, Prostate Cancer, Breast Cancer, Gastrointestinal Cancer, Lung Cancer, Brain Tumors, Cardiology, Neurological Applications, Other Applications) By Type (Diagnostic, Therapeutic) By Region (North America, Asia Pacific, Europe, Middle East & Africa, South America): Regional Outlook, Growth Potential and Segments Forecast 2024-2031

Loading...
Radiopharmaceuticals Market Size, Demand and Forecast to 2031 | Insider Market Research
  • Report ID: 198
  • No. of Pages: 120
  • Categories:
  • Published Date: July 2024

Budget constraints? Get in touch with us for special pricing

Buying Options

Original price was: $9,999.00.Current price is: $8,999.00.
Original price was: $4,999.00.Current price is: $3,999.00.
Original price was: $3,999.00.Current price is: $2,999.00.
Speak To Analyst
  • +1 (614) 602 2897
  • sales@insidermarketresearch.com
Loading...

Description

The Global Radiopharmaceuticals Market size was USD 7.9 billion in 2023 and is projected to reach USD 16.4 billion by 2031, with a CAGR of 10.6 % during the forecast period. 

Global Radiopharmaceuticals Market: Overview

The radiopharmaceuticals market is currently experiencing significant innovations across various fronts. Key advancements include enhanced supply chain management to optimize production and distribution efficiency, particularly for short half-life radiopharmaceuticals, bolstered by strategies like redundancy planning and infrastructure development. For instance, in 2022, the European Association of Nuclear Medicine (EANM) launched a new initiative to improve the supply chain for radiopharmaceuticals, focusing on enhancing the availability and reliability of these products.

Concurrently, there is a burgeoning exploration into novel radioisotopes and radiopharmaceuticals, such as alpha emitters and theranostics, promising new avenues for both diagnostics and therapy, potentially overcoming current limitations. For example, in 2023, the US Food and Drug Administration (FDA) approved the use of alpha-emitting radionuclides for the treatment of certain types of cancer, marking a significant breakthrough in the field. Progress in dosimetry and radiobiology is pivotal, focusing on refining methods to measure and optimize radiation dose and biological effects, crucial for enhancing safety and efficacy. For instance, in 2022, researchers from the University of California, Los Angeles (UCLA) developed a new dosimetry method that improved the accuracy of radiation dose calculations for patients undergoing radiation therapy.

Regulatory improvements aim to harmonize and streamline processes, particularly for innovative products, facilitating quicker clinical translation and market entry. For example, in 2023, the European Medicines Agency (EMA) launched a new regulatory framework for radiopharmaceuticals, aimed at simplifying the approval process for these products. Next-generation radiopharmaceutical formulations are emerging with advanced molecular designs and delivery approaches, promising enhanced efficacy and patient outcomes. For instance, in 2022, researchers from the University of Cambridge developed a new radiopharmaceutical that targeted specific cancer cells, resulting in improved treatment outcomes.

Expansion in research and clinical trials is pivotal, driving novel and personalized approaches in disease management. For example, in 2023, the National Cancer Institute (NCI) launched a new clinical trial to investigate the use of radiopharmaceuticals in the treatment of pancreatic cancer, aiming to improve patient outcomes. Collectively, these developments underscore a dynamic and innovative landscape in the radiopharmaceuticals sector, poised to significantly impact medical imaging, diagnostics, and therapeutic interventions.

Global Radiopharmaceuticals Market: Covid-19 Impact

The COVID-19 pandemic has significantly impacted the radiopharmaceuticals market, altering demand and supply dynamics. While disruptions in production and distribution have occurred, increased usage in diagnostic imaging for COVID-19 patients has driven some market growth. However, logistical challenges and regulatory changes have posed obstacles. Future market trends may include adaptations in manufacturing processes and greater investment in research for innovative radiopharmaceutical solutions amidst evolving healthcare needs post-pandemic.

Global Radiopharmaceuticals Market: Growth Drivers

  • Advancements in Diagnostic Technologies:

Technological advancements in imaging modalities such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) have significantly boosted the demand for radiopharmaceuticals. These technologies provide precise and early detection of diseases, driving the need for radiopharmaceuticals in diagnostic procedures.

  • Increasing Incidence of Cancer and Cardiovascular Diseases:

The rising prevalence of cancer and cardiovascular diseases worldwide has bolstered the demand for radiopharmaceuticals used in both diagnosis and therapy. These conditions require accurate imaging and targeted treatment, which radiopharmaceuticals facilitate.

  • Growing Aging Population:

The global demographic shift towards an aging population has contributed to increased healthcare needs, including the demand for diagnostic tools and therapies offered by radiopharmaceuticals. Elderly populations often require more frequent medical imaging and targeted treatments, driving market growth.

Global Radiopharmaceuticals Market: Restraining Factors

  • High Cost of Radiopharmaceuticals:

Radiopharmaceuticals are often costly to produce due to the specialized manufacturing processes and stringent regulatory requirements. This high cost can limit accessibility, particularly in developing regions, and pose financial challenges for healthcare providers and patients.

  • Short Half-Life of Radiopharmaceuticals:

Many radiopharmaceuticals have short half-lives, which restricts their usability and requires efficient logistics and distribution networks. This limitation can affect their availability for diagnostic imaging and therapy, especially in regions without well-developed infrastructure.

Global Radiopharmaceuticals Market:  Opportunity Factors

  • Emerging Applications in Neurological Disorders:

There is growing research and development in using radiopharmaceuticals for diagnosing and treating neurological disorders such as Alzheimer’s disease and Parkinson’s disease. This presents significant opportunities for market expansion into new therapeutic areas.

  • Advancements in Targeted Radiopharmaceutical Therapy:

Innovations in molecular imaging and targeted therapy are opening doors for more precise and personalized treatments using radiopharmaceuticals. This trend towards personalized medicine offers opportunities for developing new products and expanding market reach.

Global Radiopharmaceuticals Market: Challenges

  • Regulatory Hurdles and Compliance Issues:

The radiopharmaceutical industry is highly regulated due to safety concerns and radiation exposure risks. Navigating complex regulatory frameworks in different countries can be challenging and time-consuming, impacting product development timelines and market entry strategies.

  • Supply Chain Constraints and Logistics:

Radiopharmaceuticals require specialized handling and transportation due to their short half-lives and radioactive properties. Ensuring a reliable supply chain, from production to distribution and administration, is crucial but poses logistical challenges that can affect market growth and accessibility.

Global Radiopharmaceuticals Market: Segmentation

Based on End User: The market is segmented into Hospitals and Clinics, Medical Imaging Centers, Others.

Based on Radioisotope: The market is segmented into Technetium 99m, Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, Others.

Based on Application: The market is segmented into Cancer, Prostate Cancer, Breast Cancer, Gastrointestinal Cancer, Lung Cancer, Brain Tumors, Cardiology, Neurological Applications, Other Applications.

Based on Type: The market is segmented into Diagnostic, Therapeutic.

Global Radiopharmaceuticals Market: Regional Insights

  • North America:

The North American radiopharmaceuticals market is experiencing robust growth driven by advancements in medical imaging technologies and increasing prevalence of chronic diseases such as cancer and cardiovascular disorders. Radiopharmaceuticals play a critical role in diagnostic procedures like PET and SPECT scans, enabling precise visualization of physiological processes at a molecular level.

For instance, in 2022, the US Food and Drug Administration (FDA) approved the use of alpha-emitting radionuclides for the treatment of certain types of cancer, marking a significant breakthrough in the field. This approval presents an opportunity for companies to enhance their offerings and market shares by catering to the demand for radiopharmaceuticals in oncology applications.

Government support and initiatives are also contributing to market growth. For example, the US government has invested in the development of 5G networks, which will enable faster and more reliable data transmission for medical imaging and other applications. Additionally, the European Union has launched initiatives to promote the development of radiopharmaceuticals, such as the European Union’s Horizon 2020 program, which provides funding for research and innovation projects.

The market is characterized by several key players, including Cardionovum AG, GE Healthcare, and Lantheus Medical Imaging, among others. These companies focus on research and development, as well as strategic collaborations and acquisitions, to expand their product portfolios and maintain their market position.

  • Asia Pacific:

The Asia Pacific radiopharmaceuticals market is experiencing significant growth driven by advancements in nuclear medicine and rising prevalence of chronic diseases. Radiopharmaceuticals, which are radioactive compounds used in diagnostic and therapeutic procedures, play a crucial role in detecting and treating various conditions such as cancer and cardiovascular diseases.

Countries like China, Japan, and India are pivotal in the market’s expansion. For instance, the Chinese government launched the “Digital China” initiative in 2023, which aims to accelerate the country’s digital transformation, including investments in medical imaging technologies. This government-backed program has spurred enterprises in China to invest in advanced radiopharmaceutical solutions.

Technological innovations in imaging techniques like PET (positron emission tomography) and SPECT (single photon emission computed tomography) are further fuelling market demand. The Japanese government has been providing significant funding for research and development in the field of radiopharmaceuticals, leading to the development of cutting-edge technologies.

However, regulatory challenges and concerns regarding radiation exposure remain key constraints. Despite these challenges, the Asia Pacific region presents significant opportunities for market players investing in research, development, and commercialization of radiopharmaceuticals, aiming to capitalize on the region’s burgeoning healthcare needs and improving healthcare infrastructure.

Global Radiopharmaceuticals Market: Competitive Landscape

ITM Isotope Technologies Munich SE, GE Healthcare, Clarity Pharmaceuticals, Isotopia Molecular Imaging, Novartis AG, NorthStar Medical Radioisotopes, Eckert & Ziegler, Eli Lilly and Company, The State Atomic Energy Corporation ROSATOM, Eczacibasi, PRECIRIX, Jubilant Pharmova Limited, Curium Pharma, South African Nuclear Energy Corporation (Necsa), Cardinal Health, Lantheus, Bayer AG, Bracco, Actinium Pharmaceuticals, Inc., Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Limited, SOFIE, Nihon Medi-Physics Co. Ltd.

Global Radiopharmaceuticals Market: Recent Developments

  • On June 21, 2024, Bayer AG, in collaboration with Charite – Universitatsmedizin Berlin, unveiled plans for the establishment of the Berlin Center for Gene and Cell Therapies. This initiative is receiving significant financial backing and support from both the German Federal Government and the State of Berlin. The joint effort aims to accelerate the delivery of ground breaking gene and cell therapies to patients, while also fostering a prominent biotech ecosystem for innovative treatments in Berlin.
  • On May 30, 2024, Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and a wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BlueRock’s investigational cell therapy, bemdaneprocel, for the treatment of Parkinson’s disease.
  • On May 2, 2024, Novartis disclosed its agreement to acquire Mariana Oncology, a biotechnology company based in Watertown, Massachusetts. Mariana Oncology focuses on the development of novel radioligand therapies (RLTs) for treating cancers with significant unmet medical needs.

Table of Content

a:2:{i:0;a:3:{s:5:”title”;s:16:”Table of Content”;s:2:”id”;s:16:”table-of-content”;s:7:”content”;s:13558:”CHAPTER 1: EXECUTIVE SUMMARY
1.1. SummaryCHAPTER 2: RESEARCH METHODOLOGY2.1. Research Process2.2. Primary Research2.3. Secondary Research2.4. Market Size Estimation2.5. Research Methodology2.6. Analyst Tools/Models/Techniques2.6.1. Notations2.7. Market Scope & Segmentation2.8. Currency & Pricing ConsideredCHAPTER 3: MARKET TRENDS3.1. Introduction3.2. Drivers3.2.1. Advancements in Diagnostic Technologies3.3. Restraints3.3.1. High Cost of Radiopharmaceuticals3.4. Opportunities3.4.1. Emerging Applications in Neurological Disorders3.5. Challenges3.5.1. Regulatory Hurdles and Compliance Issues3.6. Investment Feasibility Analysis3.7. Latest TrendsCHAPTER 4: MARKET ASSESSMENT4.1. Porters Five Forces Analysis4.1.1. Bargaining Power of Suppliers4.1.2. Bargaining Power of Buyers4.1.3. Threat of New Entrants4.1.4. Threat of Substitute4.1.5. Intensity of Competitive Rivalry4.2. Value Chain Analysis4.3. Market Share Analysis4.4. Impact of Key Regulations on the Market4.5. SWOT Analysis4.6. PESTEL Analysis4.7. Patent Analysis4.7.1. By Type4.7.2. By Radioisotope4.7.3. By Application4.7.4. By End User4.8. Roadmap Development4.9. Market Lineage Outlook4.9.1. Parent Market Outlook4.9.2. Ancillary Market OutlookCHAPTER 5: IMPACT OF RECESSION ON THE MARKET5.1. Introduction5.1.1. Short Term Impact5.1.2. Long Term ImpactCHAPTER 6: GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE6.1. Introduction6.1.1. Market Size & Forecast6.1.2. Global Radiopharmaceuticals Market Share, By Type -2023 and 2031 (%)6.2. DIAGNOSTIC6.2.1. Key market Trends, Growth Factors, and Opportunities6.2.2. Market Size and Forecast, by Regions6.3. THERAPEUTIC6.3.1. Key market Trends, Growth Factors, and Opportunities6.3.2. Market Size and Forecast, by RegionsCHAPTER 7: GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE7.1. Introduction7.1.1. Market Size & Forecast7.1.2. Global Radiopharmaceuticals Market Share, By Radioisotope -2023 and 2031 (%)7.2. TECHNETIUM 99M7.2.1. Key market Trends, Growth Factors, and Opportunities7.2.2. Market Size and Forecast, by Regions7.3. GALLIUM 687.3.1. Key market Trends, Growth Factors, and Opportunities7.3.2. Market Size and Forecast, by Regions7.4. IODINE I7.4.1. Key market Trends, Growth Factors, and Opportunities7.4.2. Market Size and Forecast, by Regions7.5. FLUORINE 187.5.1. Key market Trends, Growth Factors, and Opportunities7.5.2. Market Size and Forecast, by Regions7.6. COPPER 647.6.1. Key market Trends, Growth Factors, and Opportunities7.6.2. Market Size and Forecast, by Regions7.7. STRONTIUM 897.7.1. Key market Trends, Growth Factors, and Opportunities7.7.2. Market Size and Forecast, by Regions7.8. RADIUM 2237.8.1. Key market Trends, Growth Factors, and Opportunities7.8.2. Market Size and Forecast, by Regions7.9. ACTINIUM 2257.9.1. Key market Trends, Growth Factors, and Opportunities7.9.2. Market Size and Forecast, by Regions7.10. COPPER 677.10.1. Key market Trends, Growth Factors, and Opportunities7.10.2. Market Size and Forecast, by Regions7.11. TERBIUM 1617.11.1. Key market Trends, Growth Factors, and Opportunities7.11.2. Market Size and Forecast, by Regions7.12. ZIRCONIUM 897.12.1. Key market Trends, Growth Factors, and Opportunities7.12.2. Market Size and Forecast, by RegionsCHAPTER 8: GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER8.1. Introduction8.1.1. Market Size & Forecast8.1.2. Radiopharmaceuticals Market Share, By End User -2023 and 2031 (%)8.2. HOSPITALS AND CLINICS8.2.1. Key market Trends, Growth Factors, and Opportunities8.2.2. Market Size and Forecast, by Regions8.3. MEDICAL IMAGING CENTRES8.3.1. Key market Trends, Growth Factors, and Opportunities8.3.2. Market Size and Forecast, by Regions8.4. OTHERS8.4.1. Key market Trends, Growth Factors, and Opportunities8.4.2. Market Size and Forecast, by RegionsCHAPTER 9: GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION9.1. Introduction9.1.1. Market Size & Forecast9.1.2. Global Radiopharmaceuticals Market Share, By Application -2023 and 2031 (%)9.2. CANCER9.2.1. Key market Trends, Growth Factors, and Opportunities9.2.2. Market Size and Forecast, by Regions9.3. PROSTATE CANCER9.3.1. Key market Trends, Growth Factors, and Opportunities9.3.2. Market Size and Forecast, by Regions9.4. BREAST CANCER9.4.1. Key market Trends, Growth Factors, and Opportunities9.4.2. Market Size and Forecast, by Regions9.5. GASTROINTESTINAL CANCER9.5.1. Key market Trends, Growth Factors, and Opportunities9.5.2. Market Size and Forecast, by Regions9.6. LUNG CANCER9.6.1. Key market Trends, Growth Factors, and Opportunities9.6.2. Market Size and Forecast, by Regions9.7. BRAIN TUMOURS9.7.1. Key market Trends, Growth Factors, and Opportunities9.7.2. Market Size and Forecast, by Regions9.8. CARDIOLOGY9.8.1. Key market Trends, Growth Factors, and Opportunities9.8.2. Market Size and Forecast, by Regions9.9. NEUROLOGICAL APPLICATIONS9.9.1. Key market Trends, Growth Factors, and Opportunities9.9.2. Market Size and Forecast, by Regions9.10. OTHER9.10.1. Key market Trends, Growth Factors, and Opportunities9.10.2. Market Size and Forecast, by RegionsCHAPTER 10: NORTH AMERICA MARKET ANALYSIS10.1. Introduction10.2. RADIOPHARMACEUTICALS MARKET by Country10.3. North America RADIOPHARMACEUTICALS MARKET by Country, USD Million 2019-203110.3.1. Market Size & Forecast, By Type10.3.2. Market Size & Forecast, By Radioisotope10.3.3. Market Size & Forecast, By End User10.3.4. Market Size & Forecast, By Application10.4. U.S.10.4.1. Market Size & Forecast, By Type10.4.2. Market Size & Forecast, By Radioisotope10.4.3. Market Size & Forecast, By End User10.4.4. Market Size & Forecast, By Application10.5. Canada10.5.1. Market Size & Forecast, By Type10.5.2. Market Size & Forecast, By Radioisotope10.5.3. Market Size & Forecast, By End User10.5.4. Market Size & Forecast, By ApplicationCHAPTER 11: EUROPE MARKET ANALYSIS11.1. Introduction11.2. RADIOPHARMACEUTICALS MARKET by Country11.3. Europe RADIOPHARMACEUTICALS MARKET by Country, USD Million 2019-203111.3.1. Market Size & Forecast, By Type11.3.2. Market Size & Forecast, By Radioisotope11.3.3. Market Size & Forecast, By End User11.3.4. Market Size & Forecast, By Application11.4. Germany11.4.1. Market Size & Forecast, By Type11.4.2. Market Size & Forecast, By Radioisotope11.4.3. Market Size & Forecast, By End User11.4.4. Market Size & Forecast, By Application11.5. France11.5.1. Market Size & Forecast, By Type11.5.2. Market Size & Forecast, By Radioisotope11.5.3. Market Size & Forecast, By End User11.5.4. Market Size & Forecast, By Application11.6. U.K.11.6.1. Market Size & Forecast, By Type11.6.2. Market Size & Forecast, By Radioisotope11.6.3. Market Size & Forecast, By End User11.6.4. Market Size & Forecast, By Application11.7. Italy11.7.1. Market Size & Forecast, By Type11.7.2. Market Size & Forecast, By Radioisotope11.7.3. Market Size & Forecast, By End User11.7.4. Market Size & Forecast, By Application11.8. Spain11.8.1. Market Size & Forecast, By Type11.8.2. Market Size & Forecast, By Radioisotope11.8.3. Market Size & Forecast, By End User11.8.4. Market Size & Forecast, By Application11.9. Benelux11.9.1. Market Size & Forecast, By Type11.9.2. Market Size & Forecast, By Radioisotope11.9.3. Market Size & Forecast, By End User11.9.4. Market Size & Forecast, By Application11.10. Rest of Europe11.10.1. Market Size & Forecast, By Type11.10.2. Market Size & Forecast, By Radioisotope11.10.3. Market Size & Forecast, By End User11.10.4. Market Size & Forecast, By ApplicationCHAPTER 12: ASIA-PACIFIC MARKET ANALYSIS12.1. Introduction12.2. RADIOPHARMACEUTICALS MARKET by Country12.3. Asia Pacific Radiopharmaceuticals Market by Country, USD Million 2019-203112.3.1. Market Size & Forecast, By Type12.3.2. Market Size & Forecast, By Radioisotope12.3.3. Market Size & Forecast, By End User12.3.4. Market Size & Forecast, By Application12.4. China12.4.1. Market Size & Forecast, By Type12.4.2. Market Size & Forecast, By Radioisotope12.4.3. Market Size & Forecast, By End User12.4.4. Market Size & Forecast, By Application12.5. India12.5.1. Market Size & Forecast, By Type12.5.2. Market Size & Forecast, By Radioisotope12.5.3. Market Size & Forecast, By End User12.5.4. Market Size & Forecast, By Application12.6. Japan12.6.1. Market Size & Forecast, By Type12.6.2. Market Size & Forecast, By Radioisotope12.6.3. Market Size & Forecast, By End User12.6.4. Market Size & Forecast, By Application12.7. Australia12.7.1. Market Size & Forecast, By Type12.7.2. Market Size & Forecast, By Radioisotope12.7.3. Market Size & Forecast, By End User12.7.4. Market Size & Forecast, By Application12.8. South Korea12.8.1. Market Size & Forecast, By Type12.8.2. Market Size & Forecast, By Radioisotope12.8.3. Market Size & Forecast, By End User12.8.4. Market Size & Forecast, By Application12.9. Southeast Asia12.9.1. Market Size & Forecast, By Type12.9.2. Market Size & Forecast, By Radioisotope12.9.3. Market Size & Forecast, By End User12.9.4. Market Size & Forecast, By Application12.10. Rest of Asia Pacific12.10.1. Market Size & Forecast, By Type12.10.2. Market Size & Forecast, By Radioisotope12.10.3. Market Size & Forecast, By End User12.10.4. Market Size & Forecast, By ApplicationCHAPTER 13: LATIN AMERICA AND THE CARIBBEAN MARKET ANALYSIS13.1. Introduction13.2. RADIOPHARMACEUTICALS MARKET by Country13.3. Latin America RADIOPHARMACEUTICALS MARKET by Country, USD Million 2019-203113.3.1. Market Size & Forecast, By Type13.3.2. Market Size & Forecast, By Radioisotope13.3.3. Market Size & Forecast, By End User13.3.4. Market Size & Forecast, By Application13.4. Brazil13.4.1. Market Size & Forecast, By Type13.4.2. Market Size & Forecast, By Radioisotope13.4.3. Market Size & Forecast, By End User13.4.4. Market Size & Forecast, By Application13.5. Mexico13.5.1. Market Size & Forecast, By Type13.5.2. Market Size & Forecast, By Radioisotope13.5.3. Market Size & Forecast, By End User13.5.4. Market Size & Forecast, By Application13.6. Rest of Latin America13.6.1. Market Size & Forecast, By Type13.6.2. Market Size & Forecast, By Radioisotope13.6.3. Market Size & Forecast, By End User13.6.4. Market Size & Forecast, By ApplicationCHAPTER 14: THE MIDDLE EAST AND AFRICA MARKET ANALYSIS14.1. Introduction14.2. Radiopharmaceuticals Market by Country14.3. MEA Radiopharmaceuticals Market by Country, USD Million 2019-203114.3.1. Market Size & Forecast, By Type14.3.2. Market Size & Forecast, By Radioisotope14.3.3. Market Size & Forecast, By End User14.3.4. Market Size & Forecast, By Application14.4. South Africa14.4.1. Market Size & Forecast, By Type14.4.2. Market Size & Forecast, By Radioisotope14.4.3. Market Size & Forecast, By End User14.4.4. Market Size & Forecast, By Application14.5. Saudi Arabia14.5.1. Market Size & Forecast, By Type14.5.2. Market Size & Forecast, By Radioisotope14.5.3. Market Size & Forecast, By End User14.5.4. Market Size & Forecast, By Application14.6. UAE14.6.1. Market Size & Forecast, By Type14.6.2. Market Size & Forecast, By Radioisotope14.6.3. Market Size & Forecast, By End User14.6.4. Market Size & Forecast, By Application14.7. Rest of MEA14.7.1. Market Size & Forecast, By Type14.7.2. Market Size & Forecast, By Radioisotope14.7.3. Market Size & Forecast, By End User14.7.4. Market Size & Forecast, By ApplicationCHAPTER 15: COMPETITIVE LANDSCAPE15.1. Introduction15.2. Market Player Positioning, 202215.3. Company Evaluation Matrix15.4. Product Mapping of Top 10 Player15.5. Market Opportunities and Future Trends15.6. Competitive Heatmap15.7. Top Winning Growth Strategies15.7.1. Major Growth Strategies15.7.2. Expansion15.7.3. Merger and Acquisition15.7.4. Other DevelopmentsCHAPTER 16: COMPANY PROFILES16.1. ITM ISOTOPE TECHNOLOGIES16.1.1. Company Overview16.1.2. Key Executives16.1.3. Financial Overview16.1.4. Business Applicationnalysis16.1.5. Product Portfolio16.1.6. Key Strategic Developments16.2. GE HEALTHCARE16.3. CLARITY PHARMACEUTICALS16.4. ISOTOPIA MOLECULAR IMAGING16.5. NOVARTIS AG16.6. NORTHSTAR MEDICAL RADIOISOTOPES16.7. ECKERT & ZIEGLER16.8. ELI LILLY AND COMPANY16.9. THE STATE ATOMIC ENERGY CORPORATION ROSATOM16.10. ECZACIBASI16.11. PRECIRIX16.12. JUBILANT PHARMOVA LIMITED16.13. CURIUM PHARMA16.14. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA)16.15. CARDINAL HEALTH16.16. LANTHEUS16.17. BAYER AG16.18. BRACCO16.19. ACTINIUM PHARMACEUTICALS, INC.16.20. FUSION PHARMACEUTICALS INC.16.21. TELIX PHARMACEUTICALS LIMITED16.22. SOFIE16.23. NIHON MEDI-PHYSICS CO. LTD16.24. OTHERS”;}i:1;a:3:{s:5:”title”;s:16:”Tables & Figures”;s:2:”id”;s:14:”tables-figures”;s:7:”content”;s:16473:”LIST OF TABLESTable 1. Global Radiopharmaceuticals Market INDUSTRY SNAPSHOT, 2022-2031Table 2. Global Radiopharmaceuticals Market SHARE, By Type -2019-2031 (USD MILLION)Table 3. Global Radiopharmaceuticals Market DIAGNOSTIC, BY REGION-2019-2031 (USD MILLION)Table 4. Global Radiopharmaceuticals Market THERAPEUTIC, BY REGION-2019-2031 (USD MILLION)Table 5. Global Radiopharmaceuticals Market SHARE, By Radioisotope SIZE-2019-2031 (USD MILLION)Table 6. Global Radiopharmaceuticals Market TECHNETIUM 99M, BY REGION-2019-2031 (USD MILLION)Table 7. Global Radiopharmaceuticals Market GALLIUM 68, BY REGION-2019-2031 (USD MILLION)Table 8. Global Radiopharmaceuticals Market IODINE I, BY REGION-2019-2031 (USD MILLION)Table 9. Global Radiopharmaceuticals Market FLUORINE 18, BY REGION-2019-2031 (USD MILLION)Table 10. Global Radiopharmaceuticals Market COPPER 64, BY REGION-2019-2031 (USD MILLION)Table 11. Global Radiopharmaceuticals Market STRONTIUM 89, BY REGION-2019-2031 (USD MILLION)Table 12. Global Radiopharmaceuticals Market RADIUM 223, BY REGION-2019-2031 (USD MILLION)Table 13. Global Radiopharmaceuticals Market ACTINIUM 225, BY REGION-2019-2031 (USD MILLION)Table 14. Global Radiopharmaceuticals Market COPPER 67, BY REGION-2019-2031 (USD MILLION)Table 15. Global Radiopharmaceuticals Market , ZIRCONIUM 89, BY REGION-2019-2031 (USD MILLION)Table 16. Global Radiopharmaceuticals Market OTHERS, BY REGION-2019-2031 (USD MILLION)Table 17. Global Radiopharmaceuticals Market SHARE, By End User -2019-2031 (USD MILLION)Table 18. Global Radiopharmaceuticals Market HOSPITALS AND CLINICS, BY REGION-2019-2031 (USD MILLION)Table 19. Global Radiopharmaceuticals Market MEDICAL IMAGING CENTRES, BY REGION-2019-2031 (USD MILLION)Table 20. Global Radiopharmaceuticals Market OTHERS, BY REGION-2019-2031 (USD MILLION)Table 21. Global Radiopharmaceuticals Market SHARE, By Application -2019-2031 (USD MILLION)Table 22. Global Radiopharmaceuticals Market CANCER, BY REGION-2019-2031 (USD MILLION)Table 23. Global Radiopharmaceuticals Market PROSTATE CANCER, BY REGION-2019-2031 (USD MILLION)Table 24. Global Radiopharmaceuticals Market BREAST CANCER, BY REGION-2019-2031 (USD MILLION)Table 25. Global Radiopharmaceuticals Market GASTROINTESTINAL CANCER, BY REGION-2019-2031 (USD MILLION)Table 26. Global Radiopharmaceuticals Market LUNG CANCER, BY REGION-2019-2031 (USD MILLION)Table 27. Global Radiopharmaceuticals Market BRAIN TUMOURS, BY REGION-2019-2031 (USD MILLION)Table 28. Global Radiopharmaceuticals Market CARDIOLOGY, BY REGION-2019-2031 (USD MILLION)Table 29. Global Radiopharmaceuticals Market NEUROLOGICAL, BY REGION-2019-2031 (USD MILLION)Table 30. Global Radiopharmaceuticals Market OTHERS, BY REGION-2019-2031 (USD MILLION)Table 31. NORTH AMERICA RADIOPHARMACEUTICALS MARKET BY COUNTRY, USD MILLION 2019-2031Table 32. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 33. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 34. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 35. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 36. U.S. RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 37. U.S. RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 38. U.S. RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 39. U.S. RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 40. CANADA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 41. CANADA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 42. CANADA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 43. CANADA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 44. EUROPE RADIOPHARMACEUTICALS MARKET BY COUNTRY, USD MILLION 2019-2031Table 45. EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 46. EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 47. EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 48. EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 49. GERMANY RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 50. GERMANY RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 51. GERMANY RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 52. GERMANY RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 53. FRANCE RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 54. FRANCE RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 55. FRANCE RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 56. FRANCE RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 57. UK RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 58. UK RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 59. UK RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 60. UK RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 61. ITALY RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 62. ITALY RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 63. ITALY RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 64. ITALY RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 65. SPAIN RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 66. SPAIN RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 67. SPAIN RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 68. SPAIN RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 69. BENELUX RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 70. BENELUX RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 71. BENELUX RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 72. BENELUX RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 73. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 74. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 75. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 76. REST OF EUROPE RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 77. ASIA PACIFIC RADIOPHARMACEUTICALS MARKET BY COUNTRY, USD MILLION 2019-2031Table 78. ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 79. ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 80. ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 81. ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 82. CHINA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 83. CHINA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 84. CHINA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 85. CHINA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 86. INDIA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 87. INDIA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 88. INDIA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 89. INDIA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 90. JAPAN RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 91. JAPAN RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 92. JAPAN RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 93. JAPAN RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 94. AUSTRALIA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 95. AUSTRALIA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 96. AUSTRALIA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 97. AUSTRALIA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 98. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 99. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 100. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 101. SOUTH KOREA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 102. SOUTHEAST ASIA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 103. SOUTHEAST ASIA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 104. SOUTHEAST ASIA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 105. SOUTHEAST ASIA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 106. REST OF ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 107. REST OF ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 108. REST OF ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 109. REST OF ASIA PACIFIC RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 110. LATIN AMERICA RADIOPHARMACEUTICALS MARKET BY COUNTRY, USD MILLION 2019-2031Table 111. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 112. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 113. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 114. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 115. BRAZIL RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 116. BRAZIL RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 117. BRAZIL RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 118. BRAZIL RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 119. MEXICO RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 120. MEXICO RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 121. MEXICO RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 122. MEXICO RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 123. REST OF LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 124. REST OF LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 125. REST OF LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 126. REST OF LATIN AMERICA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 127. MEA RADIOPHARMACEUTICALS MARKET BY COUNTRY, USD MILLION 2019-2031Table 128. MEA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 129. MEA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 130. MEA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 131. MEA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 132. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 133. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 134. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 135. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 136. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 137. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 138. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 139. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 140. UAE RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 141. UAE RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 142. UAE RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 143. UAE RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 144. REST OF MEA RADIOPHARMACEUTICALS MARKET SHARE, By Type -2019-2031 (USD MILLION)Table 145. REST OF MEA RADIOPHARMACEUTICALS MARKET SHARE, By Radioisotope -2019-2031 (USD MILLION)Table 146. REST OF MEA RADIOPHARMACEUTICALS MARKET SHARE, By End User – 2019-2031 (USD MILLION)Table 147. REST OF MEA RADIOPHARMACEUTICALS MARKET SHARE, By Application -2019-2031 (USD MILLION)Table 148. KEY EXPANSIONS (2019-2022)Table 149. KEY MERGERS AND ACQUISITION (2019-2022)Table 150. OTHER KEY DEVELOPMENTS (2019-2022)LIST OF FIGURESFigure 1. REGIONAL ANALYSIS (2022 & 2031)Figure 2. RESEARCH PROCESSFigure 3. ANALYSIS FRAMEWORKFigure 4. IMPACT OF KEY REGULATION ON THE MARKETFigure 5. SWOT ANALYSISFigure 6. Global Radiopharmaceuticals Market SHARE, By Type -2023 & 2031 (USD MILLION)Figure 7. Global Radiopharmaceuticals Market , DIAGNOSTIC -2019-2031 (USD MILLION)Figure 8. Global Radiopharmaceuticals Market , THERAPEUTIC -2019-2031 (USD MILLION)Figure 9. Global Radiopharmaceuticals Market SHARE, By Radioisotope -2023 & 2031 (USD MILLION)Figure 10. Global Radiopharmaceuticals Market , TECHNETIUM 99M -2019-2031 (USD MILLION)Figure 11. Global Radiopharmaceuticals Market , GALLIUM 68 -2019-2031 (USD MILLION)Figure 12. Global Radiopharmaceuticals Market , IODINE I -2019-2031 (USD MILLION)Figure 13. Global Radiopharmaceuticals Market , FLUORINE 18-2019-2031 (USD MILLION)Figure 14. Global Radiopharmaceuticals Market , COPPER 64 -2019-2031 (USD MILLION)Figure 15. Global Radiopharmaceuticals Market , STRONTIUM 89 -2019-2031 (USD MILLION)Figure 16. Global Radiopharmaceuticals Market , RADIUM 223 -2019-2031 (USD MILLION)Figure 17. Global Radiopharmaceuticals Market , ACTINIUM 225 2019-2031 (USD MILLION)Figure 18. Global Radiopharmaceuticals Market , COPPER 67 -2019-2031 (USD MILLION)Figure 19. Global Radiopharmaceuticals Market , TERBIUM 161 -2019-2031 (USD MILLION)Figure 20. Global Radiopharmaceuticals Market , ZIRCONIUM 89 -2019-2031 (USD MILLION)Figure 21. Global Radiopharmaceuticals Market SHARE, By End User -2023 & 2031 (USD MILLION)Figure 22. Global Radiopharmaceuticals Market , HOSPITALS AND CLINICS -2019-2031 (USD MILLION)Figure 23. Global Radiopharmaceuticals Market , MEDICAL IMAGING CENTRES -2019-2031 (USD MILLION)Figure 24. Global Radiopharmaceuticals Market , OTHERS -2019-2031 (USD MILLION)Figure 25. Global Radiopharmaceuticals Market SHARE, By Application -2023 & 2031 (USD MILLION)Figure 26. Global Radiopharmaceuticals Market , CANCER -2019-2031 (USD MILLION)Figure 27. Global Radiopharmaceuticals Market , PROSTATE CANCER -2019-2031 (USD MILLION)Figure 28. Global Radiopharmaceuticals Market , BREAST CANCER -2019-2031 (USD MILLION)Figure 29. Global Radiopharmaceuticals Market , GASTROINTESTINAL CANCER -2019-2031 (USD MILLION)Figure 30. Global Radiopharmaceuticals Market , OTHERS -2019-2031 (USD MILLION)Figure 31. MARKET PLAYER POSITIONING, 2022Figure 32. COMPANY EVALUATION MATRIXFigure 33. PRODUCT MAPPING OF TOP 10 PLAYERSFigure 34. COMPETITIVE HEATMAP OF KEY PLAYERS”;}}

Tables & Figures

Frequently Asked Questions (FAQ):

  • Which is the leading segment in the Global Radiopharmaceuticals Market?

    Based on application, lung cancer and breast cancer are among the most commonly diagnosed cancers globally, with a considerable focus on developing innovative therapies like gene and cell therapies to improve treatment outcomes.

  • What are the key factors driving the Global Radiopharmaceuticals Market?

    The advancements in medical imaging technology and the rising prevalence of chronic diseases are some of the key factors driving the growth in the market.

  • Which region will contribute notably towards the Global Radiopharmaceuticals Market?

    North America region to contribute the major share towards the market growth.

  • What are the key players in the Global Radiopharmaceuticals Market?

    ITM Isotope Technologies Munich SE, GE Healthcare, Clarity Pharmaceuticals, Isotopia Molecular Imaging, Novartis AG, NorthStar Medical Radioisotopes, Eckert & Ziegler, Eli Lilly and Company, The State Atomic Energy Corporation ROSATOM, Eczacibasi, PRECIRIX, Jubilant Pharmova Limited, Curium Pharma, South African Nuclear Energy Corporation (Necsa), Cardinal Health, Lantheus, Bayer AG, Bracco, Actinium Pharmaceuticals, Inc., Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Limited, SOFIE, Nihon Medi-Physics Co. Ltd. and Others.

Buying Options

Original price was: $9,999.00.Current price is: $8,999.00.
Original price was: $4,999.00.Current price is: $3,999.00.
Original price was: $3,999.00.Current price is: $2,999.00.
Speak To Analyst
  • +1 (614) 602 2897
  • sales@insidermarketresearch.com